Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Drug Profile

Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging

Alternative Names: KI-0002

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kereos
  • Developer Kereos; Lantheus Medical Imaging
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Diagnosis) in USA (Injection)
  • 31 May 2010 Preclinical development of KI 0002 as an MRI agent for use in the assessment of CVD is ongoing in the US
  • 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top